Repurposing Clinically Safe Drugs to Modulate DNA Repair in CRISPR

Study Background and Research Question

Genome editing with CRISPR-Cas systems relies on the precise induction and repair of DNA double-strand breaks (DSBs). The cellular repair of these DSBs determines the eventual genetic outcome, shaping both the efficiency and accuracy of gene editing. DSBs can be resolved by several endogenous pathways, most notably non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway yields distinct mutational signatures, influencing whether targeted disruptions, precise edits, or larger deletions occur. While CRISPR editing enables targeted genetic interventions for disease modeling and therapy, the ability to bias these repair outcomes with small molecules remains a key challenge. This study addresses whether clinically safe drugs, already approved for other indications, can be systematically repurposed to modulate DNA repair pathway choice and thereby refine CRISPR outcomes (paper).

Key Innovation from the Reference Study

The central innovation of this research is a high-throughput, phenotypic drug screening platform using human induced pluripotent stem cells (hiPSCs) engineered with a doxycycline-inducible Cas9 system. By exposing these cells to over 7,000 FDA-approved drugs during CRISPR editing, the authors directly measured how each compound influences the distribution of repair pathway outcomes—NHEJ, MMEJ, and HDR. This approach not only identifies inhibitors and enhancers of specific DNA repair modalities but also uncovers compounds that can induce synthetic lethality when particular repair pathways are genetically or pharmacologically blocked (paper). Such findings open avenues for precision genome editing, combinatorial cancer therapy, and the rational tailoring of gene editing workflows.

Methods and Experimental Design Insights

The experimental platform centers on the 409B2 hiPSC line, which expresses Cas9 upon doxycycline induction (iCRISPR system). The workflow involves: (1) CRISPR-mediated editing of a defined genomic locus during drug treatment; (2) recovery of cells in standard media; (3) survival measurement via a resazurin-based fluorescence assay; and (4) deep sequencing to quantify repair outcomes. Each drug was tested in a single replicate across the screen, leveraging automation and multiplexed sequencing for scale and efficiency. The mutational outcomes at the edited locus were assigned to specific pathways—insertions (NHEJ), predictable deletions (MMEJ), and precise edits (HDR)—using sequence context and microhomology criteria (paper). This approach allowed the team to identify compounds that shift the balance among DSB repair pathways, alter cell survival after editing, or sensitize cells to synthetic lethality in the context of pathway inhibition. Additional molecular experiments, including gene silencing of ESR2 and AOX1, elucidated protein-level regulators of pathway choice and synergy with drug treatments.

Core Findings and Why They Matter

The study reveals several key findings with broad implications:

• Numerous clinically safe drugs can act as either inhibitors or enhancers of NHEJ, MMEJ, or HDR. This provides a resource for rationally tuning CRISPR editing outcomes depending on the desired end result (paper).
• Silencing of ESR2—a nuclear hormone receptor—synergistically increases HDR rates (mean 4.6-fold) when combined with NHEJ inhibition, illustrating a combinatorial strategy for boosting precise genome editing (paper).
• Synthetic lethality screens identified drugs that are selectively toxic when NHEJ or HDR is blocked, suggesting potential for targeted cancer therapies exploiting repair pathway dependencies (paper).
• The composition of DNA sequences adjacent to DSBs influences the repair pathway distribution, and drug interventions can further bias these outcomes for template-free or template-directed editing applications.

These findings empower genome engineers to purposefully modulate the outcome of CRISPR interventions—enabling more precise gene corrections for genetic disease, improving the efficacy of knock-in strategies in T-cell engineering, and enhancing the selectivity of synthetic lethality approaches in oncology.

Comparison with Existing Internal Articles

This reference study extends and complements insights from several recent internal resources. For example, "Repurposing FDA-Approved Drugs to Modulate DNA Repair in CRISPR Editing" provides a broad overview of systematic drug screening for genome editing, supporting the translational potential of repair pathway modulators for disease modeling and gene therapy. Meanwhile, articles such as "Dantrolene Sodium Salt: Precision RyR Antagonist for DNA Repair Assays" highlight ryanodine receptor antagonists—including dantrolene sodium salt—as model compounds for calcium signaling modulation in genome editing workflows. These resources collectively illustrate the intersection of calcium homeostasis, DNA repair, and synthetic lethality, with dantrolene sodium salt offering unique advantages for reproducibility and workflow flexibility in advanced CRISPR research (internal).

Limitations and Transferability

While the study offers a powerful screening resource, several limitations must be noted:

• Single-replicate screening, though high-throughput, may miss subtle or context-dependent effects; validation in multiple cell types and with orthogonal assays is advised.
• hiPSCs provide a relevant human model, but drug effects may differ in primary or disease-specific cell contexts, necessitating further validation before translational application.
• Off-target or pleiotropic actions of clinically safe drugs may confound interpretation; follow-up studies are needed to dissect direct effects on DNA repair machinery versus indirect effects via cell physiology.
• Extension of these findings to in vivo settings or complex tissue models will require additional pharmacokinetic and toxicological evaluation.

Nonetheless, the workflow is broadly adaptable and provides a template for integrating pharmacological modulators into precision genome editing and synthetic lethality screens.

Protocol Parameters

• CRISPR editing in hiPSCs | Doxycycline 2 μg/mL, Cas9 induction for 24 h | hiPSC genome editing workflows | Robust temporal control of Cas9 activity | paper
• Drug screening concentration | 10 μM (typical), single replicate | High-throughput drug repurposing | Sufficient to observe on-target and off-target effects | paper
• DNA repair quantification | Illumina sequencing, 10,000x coverage | Pathway-specific indel/HDR analysis | High-fidelity assignment of repair outcomes | paper
• Dantrolene sodium salt for RyR/Ca²⁺ modulation | 5–20 nM in DMSO | Calcium signaling studies, workflow optimization | Matches reported IC₅₀ for RyR2 inhibition | product_spec
• Calmodulin supplementation | 10 μM | RyR inhibition in cardiomyocytes | Enhances selectivity of dantrolene effects | workflow_recommendation

Research Support Resources

For researchers seeking to reproduce or extend these findings in the context of calcium signaling and DNA repair, high-purity compounds are essential for experimental reliability. Dantrolene, sodium salt (SKU B6329) is a potent ryanodine receptor antagonist with documented efficacy in modulating intracellular calcium dynamics and supporting advanced CRISPR and synthetic lethality workflows (source: product_spec). Its calmodulin-dependent mechanism and nanomolar potency make it a valuable tool for studies at the interface of calcium homeostasis and genome engineering. For practical protocol optimizations and troubleshooting strategies, see internal guidance at Dantrolene Sodium Salt: Precision RyR Antagonist for DNA Repair Assays.